| abstract |
In some embodiments, the invention provides phosphoinositide 3-kinase (PI3K) inhibitors that are selective for γ- and δ-isoforms and PI3K that are selective for both γ- and δ-isoforms. A therapeutic combination of a PI3K inhibitor, including an inhibitor, and a Breton tyrosine kinase (BTK) inhibitor is included. In some embodiments, the present invention provides macrophages, monocytes, mast cells, helper T cells, cytotoxic T cells, regulatory T cells, natural killer cells, bone marrow-derived suppressor cells, regulatory B cells, neutrophils Therapeutic methods using BTK inhibitors and PI3K-δ inhibitors to treat solid tumor cancers by modulating the tumor microenvironment including spheres, dendritic cells and fibroblasts are included. |